ライフサイエンスコーパス: interleukin-6 receptor

1 6 exerts many of its effects via the soluble interleukin-6 receptor.

2 embles cytokine receptors, which include the interleukin-6 receptor.

3 either express low or no detectable surface interleukin-6 receptor.

4 iation with ErbB-2, the EGF-receptor, or the interleukin-6 receptor.

5 t modulates inflammatory markers by blocking interleukin 6 receptors.

6 ndothelial cells, as well as deletion of the interleukin-6 receptor a on these cells, attenuated the

7 GF-alpha, cell adhesion receptor L-selectin, interleukin 6 receptor alpha subunit, beta-amyloid precu

8 ult from a transcriptional downregulation of interleukin-6 receptor alpha (IL-6Ralpha) with IL-6Rbeta

9 feron beta (IFN-beta), interleukin-6 (IL-6), interleukin-6 receptor alpha (IL-6Ralpha), soluble inter

10 te that the proportion of CD5(+) relative to interleukin-6 receptor alpha (IL-6Ralpha)-expressing B c

11 arilumab, a human monoclonal antibody, binds interleukin-6 receptor alpha and efficiently blocks the

12 The effect of the interleukin-6 receptor alpha inhibitor tocilizumab on th

13 The efficacy and safety of tocilizumab, an interleukin 6 receptor-alpha inhibitor, was assessed in

14 cient T cells showed decreased expression of interleukin-6 receptor-alpha and other Tfh cell-related

15 sGAP, AP-2, p53BP-2 (p53-binding protein-2), interleukin-6 receptor-alpha, chloride channel CLCN5, an

16 duction of interleukin-6), and serum soluble interleukin-6 receptor (an enhancer of myeloma cell resp

17 supported by direct measurements of soluble interleukin-6 receptor and interleukin-6.

18 ssociated with decreased tissue abundance of interleukin-6 receptors and STAT3.

19 7), adaptive immune response (interleukin32, interleukin 6 receptor), and reactive oxygen species (ne

20 Anakinra, monoclonal antibody to interleukin-6 receptor, and thalidomide each have led to

21 vival showed improved survival in the pooled interleukin-6 receptor antagonist groups, yielding a haz

22 Tocilizumab is an interleukin-6 receptor antagonist recently described as

23 The efficacy of interleukin-6 receptor antagonists in critically ill pat

24 ng organ support in ICUs, treatment with the interleukin-6 receptor antagonists tocilizumab and saril

25 condary analyses supported efficacy of these interleukin-6 receptor antagonists.

26 uble tumor necrosis factor receptor and anti-interleukin 6 receptor antibody induce long-term (>=1 ye

27 atory drugs and glucocorticoids) to the anti-interleukin-6 receptor antibody tocilizumab (at a dose o

28 lations, the safety and efficacy of the anti-interleukin-6 receptor antibody tocilizumab in patients

29 iovascular dysfunction were treated with the interleukin-6 receptor antibody tocilizumab.

30 on and was effectively treated with the anti-interleukin-6 receptor antibody tocilizumab.

31 f locally applied Tocilizumab (TCZ), an anti-interleukin-6 receptor antibody, on experimental periodo

32 eukin-6 receptor alpha (IL-6Ralpha), soluble interleukin-6 receptor beta (sIL-6Rbeta, or gp130), IL-8

33 500, rapamycin, methylprednisolone, and anti-interleukin-6 receptor blockade (tocilizumab).

34 The efficacy of interleukin-6 receptor blockade in hospitalized patients

35 ial insights into the safety and efficacy of interleukin-6 receptor blockade in the treatment of card

36 imed to describe initial experience of using interleukin-6 receptor blockade with tocilizumab in the

37 Interleukin-6 receptor blockade with tocilizumab remains

38 f the inflammatory response, for example, by interleukin-6 receptor blockade, would appear to be bene

39 lly resolved with antifungal treatment or by interleukin-6 receptor blockade.

40 The use of interleukin-6 receptor blockers, when supported by testi

41 Interleukin 6 receptor-blocking therapy can be effective

42 cacy and safety of strategies initiating the interleukin-6 receptor-blocking monoclonal antibody toci

43 sly identified gene-protein associations for interleukin-6 receptor, chemokine CC-4, angiotensin-conv

44 cluding T cell factor-1, Ikaros, AP-1, CK-2, interleukin-6 receptor E (IL-6RE), ISRE, GAS, NF-kappaB,

45 Functional variants in the interleukin-6 receptor gene (IL6R) are associated with a

46 cilizumab (a monoclonal antibody against the interleukin-6 receptor) had a beneficial effect when pre

47 cilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better outcomes

48 Signaling by the interleukin 6 receptor (IL-6R) also activates STAT3 thro

49 s was paralleled by a down-regulation of the interleukin 6 receptor (IL-6R) on naive CD4(+) T cells o

50 r of tumor necrosis factor alpha (TNFalpha), interleukin 6 receptor (IL-6R), and epidermal growth fac

51 ver diseases, by targeting components of the interleukin-6 receptor (IL-6R) complex.

52 es of CD341 cells, simultaneous reduction of interleukin-6 receptor (IL-6R) expression on myeloid pro

53 es to map integratively the epitope of human interleukin-6 receptor (IL-6R) for two adnectins with di

54 The Asp358Ala variant in the interleukin-6 receptor (IL-6R) gene has been implicated

55 lin-like growth factor receptor (IGF-1R) and interleukin-6 receptor (IL-6R) signaling (eg, IKK/NF-kap

56 sheddase for tumor necrosis factor a (TNFa), interleukin-6 receptor (IL-6R), and several ligands of t

57 /or the clinical monoclonal antibody against interleukin-6 receptor (IL-6R), tocilizumab, prevented M

58 itors prevent shedding of both TNFR1 and the interleukin-6 receptor (IL-6Ralpha), we hypothesized tha

59 sp358Ala variant (rs2228145; A>C) in the IL (interleukin)-6 receptor ( IL6R) gene has been implicated

60 though neither Toll-like receptor (TLR)2 nor interleukin 6 receptor (IL6R) signaling is involved, a r

61 pecifically cleaved by RHBDL2, including the interleukin-6 receptor (IL6R), cell surface protease inh

62 s in the levels of interleukin-6 and soluble interleukin-6 receptor in acute meningococcal septicemia

63 s in the levels of interleukin-6 and soluble interleukin-6 receptor in acute meningococcemia may affe

64 ly that alterations in the levels of soluble interleukin-6 receptor in septic shock could affect the

65 s study sought to evaluate the effect of the interleukin-6 receptor inhibitor tocilizumab on myocardi

66 es: etanercept (TNF-inhibitor), tocilizumab (interleukin-6 receptor inhibitor) and rituximab (anti-CD

67 st-time ST-elevation MI, and tocilizumab, an interleukin-6 receptor inhibitor, reduced blood neutroph

68 ia is associated with a reduction in soluble interleukin-6 receptor levels in proportion to disease s

69 were analyzed for interleukin-6 and soluble interleukin-6 receptor levels.

70 ls are elevated in patients with MM; soluble interleukin-6 receptor may amplify circulating interleuk

71 cilizumab, a monoclonal antibody against the interleukin 6 receptor, may counteract the inflammatory

72 petuation has led to the use of an antihuman interleukin-6 receptor monoclonal antibody, tocilizumab.

73 ved by treatment with antibiotics or an anti-interleukin-6 receptor-neutralizing antibody.

74 alpha, tumor necrosis factor-alpha receptor, interleukin-6 receptor, or L-selectin.

75 protein gene, the apolipoprotein E gene, the interleukin-6 receptor protein gene, or the CRP gene its

76 humanised monoclonal antibody targeting the interleukin-6 receptor, reduced the risk of relapse in p

77 Soluble interleukin-6 receptor returns to levels seen in normal

78 rotein S[rs6123] in the schizophrenia group; Interleukin-6 receptor[rs7553796] in both the control an

79 Soluble interleukin-6 receptor serum levels are elevated in pati

80 s shows that caveolin-1 is co-localized with interleukin-6 receptor signal transducing chain gp130 an

81 ocyte receptor (GLM-R), with homology to the interleukin-6 receptor signal transducing chain, gp130,

82 on to baseline levels through suppression of interleukin-6 receptor signaling.

83 The soluble interleukin 6 receptor (sIL-6R) circulates at elevated l

84 tivation-regulated chemokine (TARC), soluble interleukin 6 receptor (sIL-6R), and soluble tumor necro

85 Generation of the soluble interleukin-6 receptor (sIL-6R) is a prerequisite for pa

86 ow PC labeling indices, higher serum soluble interleukin-6 receptor (sIL-6R) levels, and a higher pro

87 on gamma-induced protein 10 (IP-10), soluble interleukin-6 receptor (sIL-6R), sCD14, and sGP130-were

88 The primary analysis focuses on the soluble interleukin-6 receptor (sIL-6R), which is involved in mu

89 -1 receptor antagonist (IL-1Ra), and soluble interleukin-6 receptor (sIL-6R).

90 active protein [CRP], interleukin 6, soluble interleukin 6 receptor [sIL-6R], soluble gp130, tumor ne

91 thway, including janus kinase-1, gp 130, the interleukin-6 receptor, STAT1, and STAT3, were examined

92 -6 activation of janus kinase-1, gp 130, the interleukin-6 receptor, STAT1, and STAT3.

93 gle variant, as did plasma concentrations of interleukin-6 receptor subunit alpha (also based on a si

94 r's laboratory reveals that the gp130-linked interleukin-6 receptor, which usually activates STAT3 pr